Li Dong, Xie Yun, Li Qin, Sun Jiaming, Jiang Ping, Jia Yi, Murphy Diane K, Li Qingfeng
Peking University Third Hospital, Beijing, China (D.L.); Shanghai 9th People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.X., Qingfeng Li); General Hospital of Guangzhou Military Command of PLA, Guangzhou, Guang Dong, China (Qin Li); Union Hospital of Tongji Medical College of HUST, Wuhan, Hubei, China (J.S.); Nanfang Hospital, Southern Medical University, Guangzhou, China (P.J.); Allergan China, Beijing, China (Y.J.); and Allergan plc, Irvine, Calif., (D.K.M.).
Plast Reconstr Surg Glob Open. 2017 Jan 16;5(1):e1133. doi: 10.1097/GOX.0000000000001133. eCollection 2017 Jan.
Hyaluronic acid dermal fillers are effective in correcting severe nasolabial folds (NLFs) in non-Asian populations. We assessed safety and effectiveness of Juvéderm Ultra Plus in a Chinese population.
This double-blind study randomized Chinese subjects with severe NLFs to Juvéderm Ultra Plus (24 mg/mL) in 1 NLF and Restylane injectable gel (20 mg/mL) in the other NLF. NLFs were evaluated using the validated 5-point photonumeric Allergan NLF Severity Scale (0 is "no wrinkle" and 4 is "very deep wrinkle"). Investigator-assessed responder rates (primary outcome at 6 months), NLF mean improvements, and subject-assessed responder rates and preference were assessed.
Of 124 subjects randomized, 122 completed the 6-month visit. NLFs treated with Juvéderm Ultra Plus required less volume than those treated with Restylane (median [range]: 0.80 [0.3-2.0] vs 1.00 [0.3-1.9]; <0.001). Investigator-assessed responder rates were 90.4% for Juvéderm Ultra Plus and 89.6% for Restylane, establishing noninferiority of Juvéderm Ultra Plus. Mean (SD) improvements in NLF Severity Scale scores from baseline at 6 months were 1.5 (0.75) for Juvéderm Ultra Plus and 1.6 (0.73) for Restylane. Subject-assessed responder rates were similar to investigator-assessed rates (87.3%, Juvéderm Ultra Plus; 83.9%, Restylane). Of subjects reporting a preference, 62.1% preferred Juvéderm Ultra Plus. The most common treatment site responses were swelling and tenderness; most were mild or moderate in severity and resolved without intervention. Juvéderm Ultra Plus had fewer severe treatment site responses than Restylane.
In this study in Chinese subjects, Juvéderm Ultra Plus was safe and effective for correcting severe NLFs.
透明质酸真皮填充剂在非亚洲人群中矫正重度鼻唇沟(NLF)有效。我们评估了乔雅登极致在中国人中的安全性和有效性。
这项双盲研究将患有重度NLF的中国受试者随机分为两组,一侧鼻唇沟注射乔雅登极致(24mg/mL),另一侧鼻唇沟注射瑞蓝注射用凝胶(20mg/mL)。使用经过验证的5分数字式艾尔建鼻唇沟严重程度量表(0表示“无皱纹”,4表示“非常深的皱纹”)评估鼻唇沟。评估研究者评估的反应率(6个月时的主要结局)、鼻唇沟平均改善情况、受试者评估的反应率和偏好。
124名随机分组的受试者中,122名完成了6个月的访视。乔雅登极致治疗的鼻唇沟所需填充量少于瑞蓝治疗的鼻唇沟(中位数[范围]:0.80[0.3 - 2.0]对1.00[0.3 - 1.9];<0.001)。研究者评估的乔雅登极致反应率为90.4%,瑞蓝为89.6%,证实乔雅登极致不劣于瑞蓝。6个月时鼻唇沟严重程度量表评分相对于基线的平均(标准差)改善值,乔雅登极致为1.5(0.75),瑞蓝为1.6(0.73)。受试者评估的反应率与研究者评估的反应率相似(乔雅登极致为87.